positive result

[키워드] 1:1 Activation age All participants anticipated baseline blinded block sizes blocked blood sample Canada Chloroquine circulating cirrhosis clinical clinician composite endpoint computer-generated Concomitant medication correlation Course COVID-19 COVID-19 negative criteria deficiency determine diabete diagnostic disease severity dissemination ECG element Encephalopathy endothelial Enrollment extension FIVE fixed Follow-up G6PD HCQ HCW Health care worker Hepatitis high risk hospital Hospitalization Hospitalized Host Hydroxychloroquine immune include individually randomized insulin intensive care units Intervention intervention arm intubation investigator Laboratory Liver disease Long marker microbiologically Mortality multisite neutralize non-invasive ventilation non-specific number objective offered Older open label Oropharyngeal outcome outcome measure parallel-group participant patients per day Placebo placebo-controlled plasma porphyria positive positive result pregnant Prevent Primary outcome Prophylaxis Protecting protocol Psychological distress psychological Impact QTc QTc interval randomised randomised placebo controlled trial reactive reduce Registered renal reported Research Respiratory failure risk of COVID-19 Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 virus secondary Seroconversion serology Standard status study period Study protocol Support symptom duration symptomatic syndrome Tablet tablets term Toronto Trial two group Two-arm undergo use of hydroxychloroquine ventilator viral PCR Viral RNA website worker
[DOI] 10.1186/s13063-020-04577-8 PMC 바로가기 [Article Type] Letter